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The human immunodeficiency virus type 1 (HIV) Tat
protein, a potent activator of HIV gene expression,
is essential for integrated viral genome expression
and represents a potential antiviral target. Tat binds
the 50-terminal region of HIV mRNA’s stem-bulge-
loop structure, the transactivation-responsive (TAR)
element, to activate transcription. We find that dide-
hydro-Cortistatin A (dCA), an analog of a natural
steroidal alkaloid from a marine sponge, inhibits
Tat-mediated transactivation of the integrated
provirus by binding specifically to the TAR-binding
domain of Tat. Working at subnanomolar concentra-
tions, dCA reduces Tat-mediated transcriptional
initiation/elongation from the viral promoter to inhibit
HIV-1 and HIV-2 replication in acutely and chronically
infected cells. Importantly, dCA abrogates sponta-
neous viral particle release from CD4+T cells from
virally suppressed subjects on highly active antire-
troviral therapy (HAART). Thus, dCA defines a unique
class of anti-HIV drugs that may inhibit viral produc-
tion from stable reservoirs and reduce residual
viremia during HAART.
INTRODUCTION
Although treatment with antiretroviral drugs (ARVs) has extended
the quality and expectancy of life for people infected with HIV, it
has been unsuccessful in curing HIV infection. ARVs fall into
the following major classes: fusion inhibitors (FIs), nucleoside
reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse
transcriptase inhibitors (NNRTIs), nucleotide reverse transcrip-
tase inhibitors (NtRTIs), protease inhibitors (PIs), and integrase
inhibitors (INIs). Highly active antiretroviral therapy (HAART) is
based on triple or quadruple combinations of ARVs (Gulick
et al., 1997; Hammer et al., 1997); however, while reducing HIV
to very low levels, this treatment fails to eliminate the infection
completely (Chun et al., 1997; Finzi et al., 1997; Wong et al.,Ce1997). Ultrasensitive assays revealed that HIV persists in latently
and productively infected CD4+T cells in the peripheral blood
of HAART-receiving individuals who have maintained undetect-
able plasma viremia for prolonged periods of time (Chun et al.,
2005; Palmer et al., 2008). Residual viremia is not affected by
the addition of an INI or a FI to a stable HAART regimen (Dinoso
et al., 2009; Gandhi et al., 2010; Yukl et al., 2010), suggesting that
it originates from long-lived stable reservoirs that contain an inte-
grated provirus that continuously produces viral particles
despite HAART. Viral production from these cellular reservoirs,
resulting from continuous transcription of an integrated viral
genome, is not affected by current ARVs. As such, other classes
of ARVs are needed to inhibit this process.
Tat is a 14 kDa protein that is synthesized from an mRNA
joined from two coding exons. The first exon encodes amino
acids 1–72, and (in most strains of HIV-1) the second exon
encodes amino acids 73–101. An N-terminal 86 amino acid
form of Tat produced in a few laboratory-passaged virus
strains is frequently used to study Tat. This potent activator
of HIV gene expression is essential for the synthesis of full-
length transcripts of the integrated viral genome by RNA poly-
merase II (RNAPII) (Okamoto and Wong-Staal, 1986; Selby
et al., 1989; Sodroski et al., 1985). Tat mediates association
between the host positive transcription elongation factor
(pTEFb) complex and the transactivation-responsive element
(TAR) of the nascent viral RNA to promote transcriptional elon-
gation from the viral promoter (Fujinaga et al., 1998; Laspia
et al., 1989; Mancebo et al., 1997). Given Tat’s crucial require-
ment for viral gene expression, it has been the target for the
development of several compounds (for review, see Baba,
2006; De Clercq, 1995; Richter and Palu, 2006); however,
these compounds have low efficacy in vivo, and none have
reached the clinic.
Cortistatin A (CA) is a recently discovered natural steroidal
alkaloid isolated from the marine sponge Corticium simplex
(Aoki et al., 2006), and it has been reported to display antiprolifer-
ative properties toward human umbilical vein endothelial cells
(HUVECs) with an average half-maximal inhibitory concentration
(IC50) of 0.35 mM (Aoki et al., 2006, 2007). The scarce natural
supply prompted the chemical synthesis of didehydro-Cortista-
tin A (dCA), the equipotent analog of CA, starting from the inex-
pensive and abundant steroid prednisone and requiring onlyll Host & Microbe 12, 97–108, July 19, 2012 ª2012 Elsevier Inc. 97
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Figure 1. Structure and Activity of dCA on HIV-1 Expression
(A) Structure of CA and its analog dCA.
(B) Activity of dCA on acute replication of HIV-1 at three different mois. Quantitative CPRG assay.
(C) Effect of pretreating cells with dCA on acute HIV-1 replication. HeLa-CD4 cells were either treated or not with increasing concentrations of dCA. HIV-1 pNL4-3
was added 24 hr later to the cells of both experiment sets (moi >> 10) in the presence of testing compound or DMSO control. CPRG assay was performed
48 hr later.
(D) dCA does not block HIV-1 proviral integration into host cells. HeLa-CD4 cells were infected with pNL4-3 (moi >> 1) in the presence of dCA. Total DNA was
extracted 24 hr later, and integrated provirus was determined by qPCR.
(E) Analysis of viral mRNA expression. Total RNAwas extracted 3 days after acute infection with pNL4-3 (moi >> 1) in the presence of dCA. First-strand cDNAwas
quantified by qPCR using primers directed to the env and LTR regions. Results were normalized as copies of viral mRNA per copy of GAPDHmRNA. The arbitrary
value of 1 was assigned to the amount of viral mRNA generated in the absence of dCA. RNA samples not reverse transcribed were used as negative control. Error
bars represent standard deviations.
(F) Viral mRNA expression levels upon dCA treatment of chronically infected cells. HeLa-CD4 cells chronically infected with pNL4-3 were treated with dCA for 10
or 60 days, total RNA was extracted and reverse transcribed, and viral cDNA was quantified as in (E).
(G) p24 antigen quantification. Viral supernatants recovered from cells described in (B) grown for 60 days were assayed for their p24 antigen content using
a sandwich ELISA kit. Error bars represent standard deviations.
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effective manner (Shi et al., 2009, 2011) (Figure 1A).
Here we report that dCA potently and selectively inhibits Tat-
mediated transactivation of the integrated HIV provirus. dCA
binds specifically to the TAR-binding domain of Tat and as
a consequence reduces cell-associated HIV-1 viral RNA and
capsid p24 antigen production in acutely and chronically in-
fected cultured and primary cells at an half-maximal effective
concentration (EC50) as low as 0.7 pM. Moreover, in vitro dCA
abrogates low-level virus replication from primary cells isolated
from patients undergoing HAART treatment. In total, these
results define dCA as a potential anti-HIV drug that could be
used to decrease residual viremia during HAART.
RESULTS
dCA Inhibits HIV Transcriptional Activity
Wepreviously reported that eukaryotic initiation factor 3 subunit f
(eIF3f) mediates restriction of HIV-1 RNA 30 end processing,
through the involvement of a set of factors that includes eIF3f,
the SR protein 9G8, and cyclin-dependent kinase 11 (CDK11)
(Valente et al., 2009a; Valente et al., 2009b). These data sug-
gested that a CDK11 inhibitor might possess anti-HIV activity.
Given that CA was reported to bind with high-affinity CDK11
(Cee et al., 2009), we examined the ability of its analog dCA to
decrease HIV production by interfering with CDK11 activity.
While we did not confirm an effect of dCA on CDK11 activity,
we discovered a potent activity as an inhibitor of HIV-1 transcrip-
tion (see Figures S1A and S1B available online).
HIV-1 susceptibility to dCA was assayed using a reporter cell
line that stably expresses the b-galactosidase (LacZ) gene; LacZ
expression is driven by the 50 long terminal repeat (LTR) of HIV-1
and responds to Tat expressed by an incoming virus. HeLa-
CD4-lacZ cells were infected with HIV-1 at different multiplicities
of infection (mois) in the presence of increasing concentrations of
dCA, and b-gal activity was determined (Figure 1B). Inhibition of
transcriptionwas dose dependent, with an EC50 as low as 2.6 nM
at the highest, and 0.7 pM at the lowest moi; the lower moi is
more representative of biological amounts of virus found in in-
fected subjects. Pretreatment of cells with dCA for 24 hr prior
to infection resulted in a 7-fold reduction in the EC50 (Figure 1C),
suggesting that dCA potency depends on the time of addition or
target concentration. Following acute infection, maximal inhibi-
tion leveled off at 75%–85%, possibly due to the inability of
dCA to block Tat-independent HIV transcription. Transcription
of the HIV-1 provirus is regulated by both viral and cellular tran-
scription factors. Before Tat is produced, low-level basal tran-
scription from the viral promoter is initiated by cellular factors,
such as the nuclear factor-kappa B (NF-kB) (Nabel and Balti-
more, 1987), Sp1 (Jones et al., 1986), TATA-binding protein (Ol-
sen and Rosen, 1992), and RNAPII. A desirable Tat inhibitor
should block Tat-mediated activation of the viral promoter
without affecting its basal transcription, which would result in(H) Cell viability of HeLa-CD4 cells chronically infected with pNL43 and long-term
concentrations of dCA for 12 months.
(I) Viral RNA levels upon treatment of CEM-SS cells with dCA and known antivira
indicated compounds for 7 days. Quantification of viral RNA was performed as in
independent experiments. See also Figure S1.
Cecellular toxicity, given the shared transcription factors of the
HIV promoter and cellular genes. The effective concentrations
of dCA did not compromise HeLa-CD4 cell viability, as a half-
maximal cytotoxic concentration (CC50) of 20 mM was observed
(Figures S1C and S1D).
To assess whether the viral block mediated by dCA occurs
before or after integration of proviral DNA into the host cell chro-
mosome, HeLa-CD4 cells were infected with HIV-1 and treated
with different concentrations of dCA, and total cellular DNA
was extracted for quantification of proviral DNA by real-time
quantitative PCR (qPCR). Such an early time point rules out de
novo infections. The presence of dCA did not change integrated
HIV DNA copy number as compared with DMSO-treated cells
(Figure 1D). These results are consistent with a viral block by
dCA at a step following integration of the provirus into the host
chromosome. Viral mRNA expression in cells treated with
increasing concentrations of dCAwas thenmeasured by reverse
transcription (RT) qPCR. A drastic dose-dependent reduction in
the total amount of viral RNA in infected cells was detected
(Figure 1E), suggesting that dCA inhibits transcription from the
integrated viral promoter. This conclusion was further supported
by the fact that treatment of cells that were chronically infected,
and therefore continuously shedding the virus (without incurring
new infections due to downregulation of CD4 from the cell
surface), reduced virus production to undetectable levels (Fig-
ure 1F). Treatment of chronically HIV-1-infected HeLa-CD4 cells
with dCA for 10 or 60 days resulted in a drastic reduction of viral
cellular RNA levels with an EC50 as low as 0.1 nM and an EC90
of less than 10 nM (Figure 1F). Moreover, we observed a contin-
uous reduction in viral RNA levels in the cell with increased treat-
ment times with dCA, an expected result, since Tat inhibition
decreases Tat production. Results were similar when viral
release from cells treated for 60 days was measured by p24
enzyme-linked immunosorbent assay (ELISA) (Figure 1G). Pro-
longed treatment of cells with dCA did not alter cell viability (Fig-
ure 1H). Furthermore, dCA, but not other ARVs, reduced viral
RNA levels in the lymphocytic cell line CEM-SS chronically in-
fected with pNL4-3 (Figure 1I), demonstrating that the effect of
dCA is not only cell-type independent but also that they extend
to the reduction of viral expression from cells already infected,
a result that none of the currently used ARVs is able to achieve.
dCA Is a Tat Inhibitor
To determine whether dCA directly impacts Tat-mediated tran-
scriptional activation from the viral promoter, recombinant Tat
protein was added in the presence or absence of dCA to
HeLa-CD4 cells stably expressing a construct containing the
HIV-1 50LTR promoter driving luciferase expression (LTR-Luc).
Transcriptional repression was observed in a dCA dose-depen-
dent manner (Figure 2A). Similar results were obtained when
a Tat-encoding plasmid was transfected into these cells (Fig-
ure 2B). These results suggest that dCA blocks Tat transcrip-
tional activation of the HIV-1 promoter. Reporter transcriptiontreated with dCA. MTT assay on HeLa-CD4 cells incubated with increasing
l drugs. CEM-SS cells chronically infected with pNL4-3 were treated with the
(E). Error bars represent standard deviations. Results are representative of four
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Figure 2. dCA binds to Tat and Inhibits Tat Transactivation of the HIV-1 LTR
(A) dCA prevents transactivation of the HIV-1 promoter by recombinant Tat. HeLa-CD4-LTR-Luc cells were treated with 0.1 mM recombinant Tat protein with
increasing concentrations of dCA. Chloroquine 100 mMwas added to increase Tat uptake and was added to all points except untreated wells. Luciferase activity
was measured 24 hr later using the Luciferase Assay System (Promega). Luciferase activity per protein concentration of each sample is shown as relative light
units (RLU). HI, heat inactivated.
(B) HeLa-LTR-Luc cells were transfected with 2 mg of a construct expressing Tat-flag driven by the thymidine kinase (TK) promoter. Twenty-four hours later, cells
were split and treated or not with dCA at the indicated concentrations. RLU was determined 40 hr later as in (A). DMSO point set as 100% activation.
(C) Schematic diagram of the HIV-1 Tat protein. Depicted above is the amino acid sequence of the wild-type basic domain or a mutated form deficient in binding
to the TAR loop.
(D) Structure of biotinylated dCA (Bio-dCA).
(E) dCA binds to Tat-wt, but not to TAR nonbinding mutant of Tat. HEK293T cells were transfected with flag-tagged Tat 101 aa (Tat-F-101-wt), a shorter Tat
version with 86 aa (Ta(86)-F-wt), Tat 86 aa mutated in the basic domain (Tat(86)-F-BRM), flag-tagged CDK11 (CDK11-F), flag-tagged 9G8 (9G8-F), and empty
vector control. Protein extracts recovered 40 hr later were incubated with DynabeadsMyOne Streptavidin T1 coated with either Biotin or Bio-dCA. Pulled-down
proteins were revealed by western bloting with the indicated antibodies.
(F) dCA interacts with purified recombinant Tat-wt protein. Recombinant Tat-wt protein was incubated with Bio-dCA streptavidin-coated beads in the presence
or absence of an excess of nonbiotinylated dCA (represented as molar equivalent [eq.] of Bio-dCA) and Raltegravir used as a negative control competitor.
Recombinant GST-9G8 and Tat-BRM were used as negative protein-binding control. Pulled-down proteins were revealed by western blot with anti-Tat and
anti-GST antibodies. See also Figure S2.
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was used as negative control, reflects Tat-independent activa-
tion of the HIV promoter, and accounts for 20% of maximal
activation. This result supports the notion that the observed
maximum inhibition plateau at 75%–85% during acute infection
is due to Tat-independent activity of the promoter. In line with
these results, dCA did not alter basal transcription from the
LTR promoter in the absence of Tat, nor when phorbol 12-myr-
istate 13-acetate (PMA) (Siekevitz et al., 1987) was used to acti-100 Cell Host & Microbe 12, 97–108, July 19, 2012 ª2012 Elsevier Invate promoter transcription via NF-kB (Figure S2A). Furthermore,
dCA showed no effect on TNF-a activation of an NF-kB reporter
construct (Duh et al., 1989) (Figure S2B), showing that inhibition
by dCA is independent of NF-kB. Transcription from CXCR4,
herpes simplex thymidine kinase (TK), phosphoglycerate kinase
(PGK), or CD4 promoters was also not affected by dCA (Figures
S2C and S2D).
Tat has several functional domains (Kuppuswamy et al., 1989)
(Figure 2C). Domains II and III are essential for transactivation,c.
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Figure 3. dCA Alters Tat-Flag Cellular Localization
Confocal microscopy analysis of the subcellular localization of transfected
Tat(86)-F-wt and Tat(86)-F-BRM and, where indicated, treated (24 hr) or not
with dCA. Flag epitope-tagged Tat was recognized with anti-flag and Alexa-
Fluor 568 anti-IgG. Transfections were performed in HeLa-CD4 cells. Magni-
fication, 3003. See also Figure S3.
Cell Host & Microbe
Didehydro-Cortistatin A Suppresses HIV Transcriptionand domain IV mediates TAR RNA binding and nuclear localiza-
tion. To determine whether Tat binds dCA, we synthesized a
biotinylated form of the compound (Bio-dCA) (Figure 2D).
Despite a 10-fold higher EC50 than dCA, higher concentrations
of Bio-dCA showed the same efficacy and did not compromise
the viability of the cells (Figures S2E and S2F). Bio-dCA coupled
to streptavidin-coated magnetic beads retained flag-tagged Tat
(86 aa) (Tat[86]-F-wt) or Tat (101 aa) (Tat[101]-F-wt) transiently
expressed in cells, but not a basic region Tat mutant (Tat[86]-
F-BRM) that no longer binds TAR and was therefore transactiva-
tion-incompetent (Figures 2E). Bio-dCA did not interact with the
RNA-binding protein 9G8, ABCE1 protein (used as negative
controls), nor with CDK11, which had been reported to interact
with its analog CA in vitro (Cee et al., 2009). In line with the
lack of interaction between dCA and CDK11, dCA was unable
to block in vitro CDK11 kinase activity and failed to alter the
cellular expression profile of CDK11 (Figures S1A and S1B).
To confirm that Bio-dCA interacts directly with Tat, we per-
formed pull-down experiments with recombinant purified protein
(Figure 2F). Recombinant Tat(86)-wt protein bound directly to
Bio-dCA and was competed by dCA but not by Raltegravir,
demonstrating the specificity of the interaction. As expected
from the results from transfected cells, Bio-dCA did not asso-
ciate with purified recombinant 9G8-GST or with the recombi-
nant Tat mutated at the basic region.
While it is well known that Tat accumulates in the nucleolus via
its basic region (Hauber et al., 1987; Siomi et al., 1990), Tat func-
tion in this compartment is still largely unknown. The nucleolus,
a highly organized, non-membrane-bound subcompartment, is
involved in transcription and maturation of rRNA and ribosomeCellbiogenesis as well as in apoptosis and cell-cycle control (Gerbi
et al., 2003). Some studies suggest that the nucleolus plays
a role in HIV-1 infection. First, lymphocytes isolated from in-
fected patients show abnormal nucleolar structures (Galati
et al., 2003), and second, nucleolar localization of TAR impairs
virus replication (Michienzi et al., 2000, 2002).
Given that dCA interacts with Tat via its basic domain, which is
also the nucleolar localization signal (NoLS), we wondered
whether dCA impacts Tat localization. To address this possi-
bility, we transfected HeLa-CD4 cells with a plasmid expressing
Tat(101)-F-wt and assessed Tat localization in the presence or
absence of dCA by fluorescence microscopy (Figure 3). dCA
caused a redistribution of Tat to the periphery of the nucleolus,
forming a distinctive ring-like structure (Figure 3 and Figure S3).
As expected, dCA caused the same nucleolar exclusion of
Tat(86)-F-wt, while cell viability, assessed by tubulin staining,
was not perturbed (Figure S3A). Furthermore, the redistribution
of Tat was observed in a dose-dependent manner (Figure S3B).
The Tat basic mutant was analyzed in parallel, and this protein
was completely excluded from the nucleolus both in the pres-
ence and the absence of dCA. The effect of dCA on wild-type
Tat appears to mimic the phenotype caused by the basic
domain mutation (Figure 3, Figure S3). The Tat-D2-26 mutant
lacks the transactivation domain but retains the basic domain
and shows a predominantly nucleolar localization. As expected,
in the presence of dCA, this mutant was excluded from the
nucleolus, consistent with the presence of the basic domain
(Figures S3C and S3D). The localization of fibrillarin, a compo-
nent of small nucleolar ribonucleoproteins (snoRNPs) (Aris and
Blobel, 1991; Hiscox, 2002) or of cyclin T1, a Tat-binding protein
(Wei et al., 1998), was not altered by dCA (Figures S3B and
S3C). The biotinylated form of dCA had the same effect on Tat
localization (Figure S3E). As Tat localizes to the nucleolus via
the basic region, these results support the biochemical data
showing a direct interaction of dCA with Tat via the TAR binding
domain.
dCA Blocks Transcriptional Initiation/Elongation
pTEFb is composed of cyclin T1 and cyclin-dependent kinase 9
(CDK9) and is recruited by Tat to the HIV TAR region (Peng et al.,
1998; Wei et al., 1998). pTEFb is used at many promoters,
including HIV-1, to phosphorylate serine 2 residues present in
the RNAPII C-terminal domain (CTD), converting a nonphos-
phorylated to a hyperphosphorylated RNAPII form that engages
in productive elongation (reviewed in Peterlin and Price, 2006;
Sims et al., 2004). The effects of dCA on transcription initiation
and elongation from the 50LTR by RNAPII were analyzed by
RT-qPCR and chromatin immunoprecipitation (ChIP).
For these studies, the amounts of viral RNA present at different
distances from the promoter weremeasured using sets of primer
pairs to quantify transcripts made up to 100 bp, 5.3 kb, or 8.5 kb
from the transcription start site (Figure 4A). We observed that
even in the absence of drug, elongation from the HIV-1 viral
promoter is not very efficient. In the presence of DMSO alone,
only 30% of 5.3 kb long transcripts and 6% of 8.5 kb long
transcripts are produced (Figure 4B, left). The addition of dCA
further decreased the production of longer viral RNA species in
a dose-dependent manner (Figure 4B, right), supporting the
notion that dCA inhibits elongation from the viral promoter.Host & Microbe 12, 97–108, July 19, 2012 ª2012 Elsevier Inc. 101
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Figure 4. RNAPII Elongation from Viral Promoter
Is Inhibited by dCA
(A) Schematic representation of the HIV genome and
localization of primers.
(B) HIV-1 elongation from HIV-1 promoter measured by
qPCR. (Left panel) Total RNA was recovered from chron-
ically infected HeLa cells treated with increasing amounts
of dCA for 60 days, and viral cDNA was measured by
relative RT-qPCR using the indicated primers located at
either 100 bp, 5.3 kb, or 8.5 kb downstream from the
transcript start site. All messages normalized to GAPDH
mRNA. The amounts of viral mRNA generated in the
absence of compound, measured at 100 bp from start site,
arbitrarily set at 100%. (Right panel) Plotting of data ob-
tained in left panel, setting each data point obtained with
the 100 bp primer set at 100% and comparing to results
obtained with 5.3 kb primer set. Error bars represent
standard deviations of the RT-qPCR assay. Results are
representative of three independent experiments.
(C) ChIP assay of the HIV promoter. HeLa-CD4 cells
chronically infected with pNL4-3 were treated with dCA for
4 days and flavopiridol (Flav) for 6–8 hr followed by RNAPII
ChIP. DNAwasmeasured by qPCR using the indicated set
of primers. Results are represented as percentages of
input. Error bars, ±SEM from three independent experi-
ments. *p < 0.05; **p < 0.01 (unpaired t test). Background
was an average of 0.1 ± 0.02 and 0.02 ± 0.01 (SEM) for
initiation and elongation, respectively.
(D) Schematic representation of the LTR-Luciferase
transgene and localization of primers.
(E) ChIP assay of the LTR-Luciferase. HeLa-CD4-LTR-Luc
cells were transfected with pGL4.74-Tat(101)-F-wt or
empty vector control and treated with dCA (100 nM) or
a-amanitin (a-ama) (5 mg/ml) for 48 hr followed by protein-
DNA crosslinking and ChIP as in (A) the indicated set of
primers. The ChIP background was an average of 0.008 ±
0.0006 (SEM). Error bars from qPCR (n = 3), ±SEM. This is
representative of two independent experiments. See also
Figure S4.
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measured the effect of dCA on RNAPII occupancy of the 50LTR
promoter or viral ORF with the indicated primers in HeLa-CD4
cells chronically infected with HIV-1 pNL4-3 (Figure 4C). Associ-
ation of RNAPII with the HIV promoter and ORF was significantly
decreased in the presence of dCA, in a dose-dependent manner,
while the occupancy of RNAPII on the GAPDH promoter and102 Cell Host & Microbe 12, 97–108, July 19, 2012 ª2012 Elsevier Inc.ORF was not affected (Figure 4C and Fig-
ure S4A). Flavopiridol (Flav), a CDK9 inhibitor,
was used as a positive control, and DMSO
served as negative control. These results
suggest that dCA might block not only elonga-
tion but also initiation of transcription in chroni-
cally infected cells. As transcription is reduced
and less Tat protein is made, the LTR promoter
tends to shut off with time, leading to reduced
initiation. Furthermore, dCA might reduce
Tat-mediated recruitment of chromatin-remod-
eling proteins, such as the histone acetyltrans-
ferases (HATs) p300/CBP, to the promoter
region (Benkirane et al., 1998; Easley et al.,
2010; Marzio et al., 1998). Together theseresults show dCA’s ability to inhibit RNAPII transcription from
the HIV-1 provirus.
Similar results were obtained when ChIP of RNAPII was per-
formed in HeLa-CD4 cells stably expressing the reporter LTR-
Luciferase, transfected with either empty vector control or a
plasmid encoding Tat(86)-wt and treated or not with dCA or
a-amanitin (an RNAPII inhibitor) (Figures 4D and 4E). RNAPII
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of Tat and was not affected by either a-amanitin or dCA. When
Tat was present, an2-fold enrichment of RNAPII was observed
both at the promoter and at the Luciferase ORF. This observed
enrichment, in the presence of Tat(86)-wt, was inhibited by
a-amanitin and by dCA. These results confirm that Tat-mediated
transcription from the HIV promoter is inhibited by dCA. In
contrast to a-amanitin used as a positive control for inhibition,
dCA did not alter the occupancy of RNAPII at the GAPDH
promoter and ORF (Figure S4B).
Potency and Scope of dCA Inhibition
The potency of dCA inhibition was compared with that of nine
compounds from four major ARVs (Figures 5A–5D). In a 2 day
acute infection assay with HeLa-CD4-LTR-LacZ cells, dCA
exhibited a 1.5–3 log lower EC50 than all other ARVs. Although
dCA only reduces infectivity by 75%–80% (versus 95%–100%
for the NNRTIs and INIs), this value is comparable to the NRTIs
and is better than the PIs (30%). PIs show low efficacy in this
short 48 hr assay, as they act only upon spreading from the initial
infection. Given that dCA blocks a postintegration event, this
result is unsurpassing, and it compares favorably with late-
acting compounds such as PIs. The results were similar when
viral production was determined by RT-qPCR of viral RNA in
HeLa-CD4 cells infected and treated for 4 days with one
compound from each class of inhibitors (Figure 5E). Again,
dCA consistently showed lower EC50 values (<0.1 nM) with
maximum inhibition around 80%, while other ARVs showed
complete inhibition, albeit with 100-fold or higher EC50.
We tested the susceptibility of HIV-2 to dCA inhibition. dCA
inhibited acute infection of HeLa-CD4 cells by HIV-2 (ROD/A)
with an EC50 of z5 nM (Figure 5F), as well as chronic infection
with an EC50 of z1.7 nM (Figure 5G), demonstrating the broad
potential of dCA. Furthermore, dCA excluded equally well
HIV-2 Tat protein from the nucleolus (Figures S3C and S3D).
The slightly lower efficiency of dCA in blocking HIV-2 replication
as compared to HIV-1 might be explained by the fact that unlike
the HIV-1 TAR element, which contains a single stem loop, the
HIV-2 TAR element consists of two characteristic stem-loop
structures, both of which participate in optimal Tat response.
We measured the ability of dCA to inhibit HIV-1 replication in
freshly isolated uninfected human peripheral blood mononu-
clear cells (PBMCs) stimulated with mitogen phytohaemaggluti-
nin (PHA) and interleukin 2 (IL-2). PBMCs were infected with
pNL4-3 and treated with raltegravir, saquinavir, or dCA, and
viral replication was measured by p24 ELISA. dCA inhibited
replication with an EC50 of <1 nM (Figures 5H and 5I) in primary
cells similar to that obtained with raltegravir and saquinavir;
however, a maximum inhibition plateau of 86% was observed
for dCA. dCA treatment of primary cells did not affect cell
viability, as the CC50 value was 100 mM, which is higher than
what was observed for HeLa-CD4 cells (Figure S5). HIV-1 tran-
scription is intimately linked to T cell activation due to shared
motifs between the HIV-LTR and the regulatory regions in
induced genes, namely NF-kB (Alcami et al., 1995). A large
variety of T cell stimuli activate NF-kB (Bours et al., 1992),
including PHA, IL-2, and tumor necrosis factor alpha (TNF-a)
(Arima et al., 1992). In the absence of Tat-independent
promoter activity, such as the activation mediated by NF-kB,CelldCA inhibition of HIV replication would be expected to be
higher.
To determine whether virus production by cells treated with
dCA rebounds after withdrawal of the drug, we treated HeLa-
CD4 cells chronically infected with pNL4-3 for 2 months with
dCA and measured viral RNA levels by RT-qPCR at several
time points after terminating treatment. No virus rebound
was observed even 27 days after the treatment was stopped
(Figure 5J), contrary to what is normally observed with ARVs.
Overall, these results suggest that dCA promotes rapid and
permanent silencing of the HIV promoter, which may drastically
limit the emergence of dCA-resistant viruses.
dCA Inhibits HIV Replication in Primary Cells
from Uninfected and Infected Subjects at Different
Disease Stages
The potency of dCA was further tested on spontaneous viral
output (p24 production) from primary CD4+T cells isolated from
eight viremic HIV-infected patients (Figure 6A). Cells were grown
in IL-2 to increase viability (Figure S6A). The inhibition of viral
replication mediated by dCA alone was 25%. ARVs alone,
which inhibit all new infections, inhibited replication by 40%,
while dCA and ARVs combined inhibited 60%. ARVs or dCA
did not affect viability or growth of these primary cells (Figures
S6B and S6C). dCA thus provides a significant additive effect
when used with other ARVs to supress replication in primary
CD4+T cells from HIV-viremic subjects.
We also investigated whether dCA could impact residual
viremia from virally suppressed subjects (plasma viral load
less than 50 copies/mL) receiving HAART. We isolated CD4+T
cells from PBMCs of four subjects treated for at least 3 years
who spontaneously released viral particles in vitro and grew
them in the absence of IL-2. The nonactivated state of these
cells confers them viability in vitro in the absence of IL-2 for
the duration of the experiment (Figures S6D and S6E). Using
an ultrasensitive RT-qPCR assay, in the presence of ARVs,
we observed a reduction of viral production of 99.7% at day
6 (Figure 6B). Importantly, dCA did not affect the viability of
the cells at the concentrations used. Altogether, our results
suggest that dCA is a highly potent inhibitor of the residual viral
production from CD4+T cells of virally suppressed subjects.
These results also support the prediction that higher HIV-1 inhi-
bition by dCA occurs in the absence of promoter activation by
IL-2 (mediated by NF-kB) when replication is mostly dependent
on Tat activity.
dCA Pharmacokinetics
To evaluate the in vitro and in vivo stability of dCA, an analytical
LC-MS/MS method was developed (Table 1). In vitro studies
compared murine and human hepatic microsomes (150 donor
mixed male/female pool). Sunitinib, an FDA-approved kinase
inhibitor with favorable human pharmacokinetics, was included
as a positive control. dCA was resistant to hepatic oxidative
metabolism in both human and mouse (Table 1). Based on the
encouraging microsomal data, follow-up mouse experiments
were conducted to evaluate the ability to dose dCA via oral
gavage (PO) and intraperitoneal injection (i.p.). dCA was easily
formulated (1 mg/mL in water) due to its high aqueous solubility.
C57Bl6 mice were dosed at 10 mg/kg, and drug levels wereHost & Microbe 12, 97–108, July 19, 2012 ª2012 Elsevier Inc. 103
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Figure 5. Effect of dCA on Acute Replication of HIV-1 Compared with Known Retroviral Inhibitors
(A–D) HeLa-CD4 cells were infected with HIV-1 pNL4-3 in the presence of the indicated compounds or DMSO. Forty hours postinfection, a CPRG assay was
performed. Same dCA curve plotted in graphs (A–D). Error bars represent standard deviation.
(E) Analysis of viral mRNA expression upon treatment with dCA and retroviral inhibitors. Total RNA extracted 4 days after acute infection with pNL4-3 (moi >> 1)
in the presence of drugs. Viral cDNAwas quantified by qPCR using primers recognizing the env and LTR regions. Results normalized to copies of GAPDHmRNA,
with value of 1 assigned to the DMSO control. Error bars represent standard deviation.
(F) Activity of dCA on acute HIV-2 replication. HeLa-CD4 cells infected with HIV-2 ROD/A in the presence of the indicated concentrations of dCA. Antigen p27
in the supernatant measured 5 days postinfection.
(G) Activity of dCA on chronic HIV-2 replication. HeLa-CD4 cells chronically infected with ROD/A were treated with the indicated concentrations of dCA
and antigen p27 measured 7 days posttreatment.
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A B Figure 6. dCA Activity on CD4+T Cells from
Viremic and Aviremic HIV-Infected Subjects
(A) dCA effect on CD4+T cells isolated from viremic
subjects. (A) Viral production from CD4+T cells
isolated from eight viremic subjects and grown
in IL-2 was measured in the presence or absence
of ARVs (RAL+AZT+EFV) supplemented or not
with 100 nM dCA (circle) or 1 mM dCA (square).
Viral production in the supernatant measured by
ELISA p24 and normalized to the negative control
(Mock). Statistical significance was assessed by
a paired t test.
(B) dCA effect on CD4+T cells isolated from
aviremic subjects. CD4+T cells isolated from
PBMCs from four subjects who had been treated with HAART for at least 3 years were cultured for 6 days without IL-2 in the presence of ARVs to block de novo
infection. dCA (100 nM) effect on the spontaneous release of HIV particles was assessed by measuring viral RNA in culture supernatants by ultrasensitive
RT-qPCR. See also Figure S6.
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The results impressively demonstrated that dCA could be given
either i.p. or orally. Drug levels at 1 hr after dosing were greater
than 1,000-fold the EC50 value found in the cell-based assays.
dCA concentration decreased at 6 and 24 hr, but even 24 hr
postdose, plasma drug levels for all mice were above 30 nM
(50-fold above the EC50). Most importantly, mice were still
healthy after 24 hr dCA treatment.
DISCUSSION
From the findings described herein, dCA is the most potent
anti-Tat inhibitor described to date. It binds selectively to the
basic domain of HIV Tat, a region also responsible for the
Tat-TAR interaction. Importantly, dCA has a drug-like structure,
is highly soluble in water, and displays good bioavailability in
mice. dCA inhibits both HIV-1 and HIV-2 replication in tissue
culture-adapted cells or in primary cells when used at single
digit nanomolar concentrations, with no associated toxicity at
the cellular level. dCA is very potent in the sense of having an
effect at a very low concentration. However, the efficacy of
dCA is limited by Tat-independent transcription. For these
reasons, it does not achieve the same multilog reductions
produced by ARVs. It is now clear that the slope of the dose-
response curve is a major determinant of antiviral activity
(Shen et al., 2008), and it is the high slope that gives PIs the
ability to inhibit replication by as much as 10 logs. The dose-
response curve for dCA is unusual and flattens out, resulting
in partial inhibition in acute infections. However, even though
dCA alone fails to totally inhibit acute HIV infections, due to
residual Tat-independent promoter activity, this feature is desir-
able, as it limits off-target effects from shared transcription
factors binding cellular and viral promoters, such as NF-kB.
HIV-1 lacking Tat undergoes some basal transcription;(H and I) Activity of dCA on primary cells. Freshly isolated uninfected human PBMC
alone. Cells were infected with pNL4-3 in the presence of increasing concentra
postinfection.
(J) No viral rebound upon termination of dCA treatment. (Left) HeLa-CD4-LTR-Lac
treated with dCA for another 10 days (dCA) or stopped dCA treatment for 10 day
with GAPDH mRNA. Viral mRNA output from untreated cells was assigned as 1.
genomic DNA contamination; 0.1% of the amplification of the cDNA samples is d
Same as left, but treatment was stopped for 27 days before harvest of the cells.
Cellhowever, it does not sustain a spreading infection (Verhoef
et al., 1997). Nonetheless, when chronically infected cells
were grown in 100 nM dCA for longer periods of time, 99% of
viral replication was inhibited.
dCA reduces both transcriptional initiation and elongation
from the viral promoter, which is consistent with inhibiting the
Tat-mediated conversion of hypophosphorylated RNAPII to the
hyperphosphorylated, processive form. Furthermore, termina-
tion of dCA treatment does not result in immediate virus
rebound, because the HIV promoter is transcriptionally silenced
in the absence of Tat activity, a feature that is extremely valuable,
as it may reduce the emergence of resistant HIV-1 strains.
Tat accumulates in the nucleolus via the basic region, but
whether its function in this compartment is relevant for patho-
genesis is still debated. dCA excludes Tat from the nucleolus,
most likely because its association with the Tat basic domain
inhibits Tat-RNA interactions that cause nucleolar accumulation.
Whether dCA-mediated nucleolar Tat exclusion translates into
any significant phenotypic outcome in HIV pathogenesis, other
than its effect on transcriptional activity, remains to be
addressed.
In an effort to understand the molecular basis of the only
reported antiproliferative and antimigratory activity of CA against
HUVECs (Aoki et al., 2007), a high-throughput kinome-binding
assay was performed by Cee et al. (2009). CA was reported to
bind to CDK11, CDK8, ROCK I, and ROCK II kinases in vitro.
We were unable to confirm dCA binding to CDK11, and dCA
did not inhibit the kinase activity of CDK11 in vitro, nor did it
bind to biotinylated dCA. Moreover, inhibition of CDK11 activity
would be expected to be toxic, as CDK11 knockdown severely
impairs cellular viability (Petretti et al., 2006), and at inhibitory
concentrations we observed no toxicity. How CA inhibits
HUVECs proliferation is still unclear. Unpublished observations
(P. Baran, personal communication) suggest that CA does nots were stimulated with PHA for 2 days, washed, and grown from then on in IL-2
tions of dCA, saquinavir, and raltegravir. Antigen p24 was measured 5 days
Z cells chronically infected with pNL4-3 were treated with dCA for 60 days and
s (dCA Stop). The viral mRNA copies were quantified by qPCR and normalized
RNA extracts were used in the qPCR as negative control for the presence of
ue to genomic DNA. The error represents a covariance of less than 5%. (Right)
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Table 1. Pharmacokinetics of dCA
Compound ID
Species (T1/2 in Minutes)
Human Mouse
dCA 60 181
Sunitinib 77 28
Plasma Concentration
Time (hr) Mouse PO (mM) i.p. (mM)
1 1 0.95 2.19
2 0.78 1.96
3 0.84 3.19
Average 0.85 2.45
6 1 0.34 0.52
2 0.53 0.45
3 0.71 0.9
Average 0.52 0.63
24 1 0.03 0.04
2 0.05 0.03
3 0.06 0.06
Average 0.05 0.04
(Top) Hepatic microsomal stability evaluated by incubating 1 mM of dCA,
with 0.2–1 mg/mL hepatic microsomes. The reaction was initiated by
adding NADPH (1 mM). Aliquots were removed at 0, 5, 10, 20, 40, and
60 min, and samples were analyzed by LC-MS/MS. Data are log trans-
formed and represented as half-lives. (Bottom) Pharmacokinetics of
dCA assessed in 3 C57Bl-6 mice. Drug levels were measured by
LC-MS/MS. A sample formulation 1 mg/ml dCA in water of 10 mg/kg
was dosed intraperitoneally (i.p.) via the tail vein and orally by gavage
(PO) with blood drawn at 1, 6, and 24 hr.
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CDK11. Thus, of the reported kinases to be affected by CA,
only ROCK I or ROCK II remains as being possibly inhibited by
CA resulting in blockage of HUVECs proliferation. However,
these displayed the lowest affinity for CA compared to CDK11.
Given that dCA inhibits neither CDK8 nor CDK11, the reported
binding apparently seen in the in vitro kinome assay might occur
outside the kinase active site and not have any physiologic
relevance.
Low levels of viral production persist in HIV-infected subjects
taking HAART (Chun et al., 2011) and are a major obstacle for
complete eradication of the infection (Hatano et al., 2009). dCA
treatment was extremely successful at reducing viral production
by a drastic 99.7% from primary CD4+T cells isolated from avire-
mic patients who had been under HAART treatment for a long
period of time. Furthermore, by acting additively with other
ARVs, dCA further reduced by 20% viral replication from
CD4+T cells isolated from viremic patients. Distinct from any
currently available ARVs that prevent new rounds of infection,
dCA inhibits HIV production from integrated proviral DNA, which
by its mode of action may drastically reduce the low levels of
persistent viremia observed in treated subjects (Palmer et al.,
2008). With a therapeutic index of over 8,000, dCA defines
a unique class of HIV antiviral drugs endowed with the ability
to decrease residual viremia during HAART and should be
considered as a promising drug to be included in therapeutic
eradication strategies.106 Cell Host & Microbe 12, 97–108, July 19, 2012 ª2012 Elsevier InEXPERIMENTAL PROCEDURES
Mitochondrial Metabolic Activity Assay
Mitochondrial metabolic activity (MTT) (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) assay was performed in the presence of
increasing concentrations of dCA according to the manufacturer’s protocol
(ATCC).
Evaluation of Toxicity by Flow Cytometry
PBMCs from HIV-negative subjects were incubated with increasing doses
of dCA (0.1 nM to 1 mM). Viability was measured after 24 and 72 hr of culture.
PBMCswere stained and analyseswere performed on a LSRII (BDBioscience)
flow cytometer as described (Trautmann et al., 2006). Antibodies used are
listed in the Supplemental Information.
Tat Transactivation Assay: CPRG
Detailed quantitative chlorophenol red-b-D-galactopyranoside (CPRG)-based
(Boehringer Mannheim) assay is provided in the Supplemental Information.
HIV Production in CD4+T Cells from Viremic and Virally Suppressed
Subjects
All patients provided written informed consent through our established collab-
oration with the Martin Memorial Health Systems (MMHS). CD4+ T cells were
isolated from PBMCs of HIV-infected subjects by negative magnetic selection
(StemCell) and cultured for 9 days in the presence of IL-2 (30 UI/mL) and ARVs
(AZT [180 nM], EFV [100 nM], RALT [200 nM]) and exposed to 100 nM or 1 mM
dCA. Viral productionwasmeasured in the supernatant by a sensitive in-house
ELISA specific for viral capsid protein p24 (Bounou et al., 2002).
CD4+T cells from virally suppressed subjects were cultured for 9 days in the
presence of ARVs and exposed to dCA 100 nM. Viral production was
measured by quantification of viral particle-associated RNA by ultrasensitive
two-step real-time reverse transcription quantitative PCR (RT-qPCR) as
detailed in the Supplemental Information.
Chromatin Immunoprecipitation Assay
ChIP was performed as previously described (Jablonski et al., 2010); detailed
protocol is in the Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at http://dx.doi.org/10.1016/j.chom.2012.05.016.
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